Changes in Hong Kong stocks | Hansaite-B (03378) fell more than 13% from the offer price, and the total market value is about HK$2 billion

The Zhitong Finance App learned that Hansai Tai-B (03378) fell by more than 13% and reached a new low of HK$15.05 in the intraday period, falling more than 50% from the offering price of HK$32. As of press release, it decreased by 13.4% to HK$15.06, with a turnover of HK$174.46,800 and a total market value of HK$2,061 billion.

According to reports, Hansi Aitai is a biotechnology enterprise with independent core technology and rich experience in the fields of structural biology, translational medicine, and clinical development. Currently, it has three clinical-stage drug candidates and seven pre-clinical drugs under development in the field of oncology. The company's core product, HX009, is a self-developed anti-PD-1 (an immune checkpoint receptor) /SIRPα bifunctional antibody fusion protein.

Notably, none of Hansatec's pipelines have been commercialized. On the financial side, for the first eight months of 2023, 2024, and 2025, Hansatec lost 85.16 million yuan, 117 million yuan, and 87.438 million yuan, respectively. As of October 31, 2025, cash and equivalent amounts to $133 million, and total current liabilities amounted to $220 million.